Purpose The biology of HIV-associated cancers may differ depending on immunologic and
virologic context during development. Therefore, an understanding of the burden of Kaposi's …

Background: Kaposi sarcoma (KS) remains common among HIV-infected persons. To better
understand KS etiology and to help target prevention efforts, we comprehensively examined …

Background: The introduction of combination antiretroviral therapy (cART) has led to a
significant reduction in Kaposi sarcoma (KS) incidence among people with HIV (PWH) …

Introduction Kaposi's sarcoma (KS) remains the most frequent malignancy in persons living
with HIV (PWH) in Latin America. We examined KS trends and outcomes from Latin …

Purpose Since the advent of highly active antiretroviral therapy (HAART), the incidence of
Kaposi's sarcoma (KS) among AIDS patients has declined both nationwide and in King …

Background Recent studies have suggested that Kaposi sarcoma (KS) rates might be
increasing in some racial/ethnic groups, age groups, and US regions. We estimated recent …

Background Improved survival among HIV-infected individuals on antiretroviral therapy
(ART) has focused attention on AIDS-related cancers including Kaposi sarcoma (KS) …

Importance Studies performed in the 1980s and early 1990s have shown that people who
develop Kaposi sarcoma (KS) are at higher risk of developing other cancers. The …

Objective: To compare the clinical course of patients with AIDS-related Kaposi's sarcoma
(KS) with CD4 counts> 300 cells/mm3 and undetectable HIV viral loads (VLs) to patients …

Kaposi's sarcoma (KS) is the most common HIV-associated malignancy [1]. The incidence of
KS has varied, rising steadily during the 1980s, followed by a significant decline over the …